The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Abstract
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.Methods In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncology Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib. We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care. Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2). Investigators, patients, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival (from date of randomisation to death), analysed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00656136.Findings Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo). Median overall survival was 10·8 months (95% CI 10·0-12·0) in the afatinib group and 12·0 months (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74). Median progression-free survival was longer in the afatinib group (3·3 months, 95% CI 2·79-4·40) than it was in the placebo group (1·1 months, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001). No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group. Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group. The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3). These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2. Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group. We recorded two possibly treatment-related deaths in the afatinib group.Interpretation Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.Funding Boehringer Ingelheim Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, as monotherapy, they have failed to overcome T790M-mediated resistance in patients (28, 29), because concentrations at which these irreversible TKIs overcome T790M activity pre-clinically are not achievable in humans due to dose-limiting toxicity related to non-selective inhibition of wild-type EGFR (30).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [28]
In the citing paper
“However, we know from clinical experience that afatinib is unable to inhibit T790M in the clinic due to a lack of a therapeutic window”
In the citing paper
“For example, studies of afatinib monotherapy showed a response rate of less than 10% among patients with acquired resistance to erlotinib or gefitinib, with a progression-free survival of approximately 4 months.13,15”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [13]
In the citing paper
“However, in lung cancer patients, afatinib is only effective in EGFR TKI naive EGFR mutant cancers and has a RR of < 10% in patients with NSCLC that have developed resistance to gefitinib or erlotinib (13).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [13]
In the citing paper
“neither Afatinib [76] nor Neratinib [77] nor Dacomitinib [78] demonstrated significant activity as single agent in patients harboring the T790M mutations.”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [76]
In the citing paper
“However, for EGFR T790M mutated lung cancer, it failed to overcome EGFR T790M-mediated resistance in patients [36, 37].”
In the citing paper
“Sixty-three percent of the patients in the afatinib group and 76% in the control group received ≥ one subsequent regimen (all mutation statuses).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Response rate was 7% versus 0.5%.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“In a prespecified analysis, participants with a complete or partial response to a first-line EGFR TKI whose tumors also had known EGFR mutation test results (58 [88%] of 66), the HR for PFS was significant (0.23), but the HR for OS was not (0.90) in the afatinib arm.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Some of the second-line studies included patients who had received > two previous regimens.15,23,47,48,51,65”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“The study found no improvement in the primary end point of OS between patients randomly assigned to afatinib and those randomly assigned to placebo, although PFS was longer in the afatinib group (3.3 v 1.1 months; HR, 0.38; 95% CI, 0.31 to 0.48; P < .001).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Among these 96 patients, PFS was 3.3 months for those who received afatinib and 1.0 month for those who received placebo (HR, 0.55; 95% CI, 0.31 to 0.85; P = .009).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346
Self-citationRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Research works printed but not linked: 2
- Hirsh, 2011, Symptom and health-related quality of life benefit from afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase III study (LUX-Lung 1), Proc World Conf Lung Cancer
- Atagi, 2011, LUX-Lung 4: A phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib, Proc World Conf Lung Cancer
Cited by
Sorted by citations
Items 101–200 of 988
Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
Hirsch, F. R., Janne, P. A., Eberhardt, W., Cappuzzo, F., Thatcher, N., Pirker, R., Choy, H., Kim, E. S., Paz-Ares, L. G., Gandara, D. R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ed0ff · Cited by 122
Sun, J., Ahn, M., Choi, Y., Ahn, J. S., & Park, K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.023 · Cited by 121
Self-citationKönig, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
Guo, Y., Qu, Z., Li, D., Bai, F., Xing, J., Ding, Q., Zhou, J., Yao, L., & Xu, Q. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00576-z · Cited by 113
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
Engel, J., Richters, A., Getlik, M., Tomassi, S., Keul, M., Termathe, M., Lategahn, J., Becker, C., Mayer‐Wrangowski, S. C., Grütter, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01082 · Cited by 114
Sullivan, I., & Planchard, D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2016.00076 · Cited by 119
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 112
Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.018 · Cited by 110
Recent progress on third generation covalent EGFR inhibitors
Cheng, H., Nair, S. K., & Murray, B. W. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.067 · Cited by 110
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
Ohmori, T., Yamaoka, T., Andō, K., Kusumoto, S., Kishino, Y., Manabe, R., & Sagara, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020792 · Cited by 116
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
Russo, A., Franchina, T., Ricciardi, G. R. R., Smiroldo, V., Picciotto, M., Zanghì, M., Rolfo, C. D., & Adamo, V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.07.003 · Cited by 112
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Furrukh, M. (2013) · Sultan Qaboos University medical journal · doi:10.12816/0003255 · Cited by 117
Günther, M., Lategahn, J., Juchum, M., Döring, E., Keul, M., Engel, J., Tumbrink, H. L., Rauh, D., & Laufer, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00316 · Cited by 108
A Third Shot at EGFR: New Opportunities in Cancer Therapy
Guardiola, S., Varese, M., Sánchez‐Navarro, M., & Giralt, E. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.10.004 · Cited by 109
Diarrhea associated with afatinib: an oral ErbB family blocker
Yang, J. C., Reguart, N., Barinoff, J., Köhler, J., Uttenreuther‐Fischer, M., Stammberger, U. M., O’Brien, D., Wolf, J., & Cohen, E. E. W. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.31 · Cited by 107
Self-citationAzuma, K., Kawahara, A., Sonoda, K., Nakashima, K., Tashiro, K., Watari, K., Izumi, H., Kage, M., Kuwano, M., Ono, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1866 · Cited by 108
Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S., Bai, Y., Li, J., Fang, B., Koomen, J. M., Rawal, B., Fisher, K. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1559 · Cited by 106
Self-citationAdverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
Jhaveri, K. D., Wanchoo, R., Sakhiya, V., Ross, D. W., & Fishbane, S. N. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.09.055 · Cited by 106
Afatinib—new therapy option for EGFR-mutant lung cancer
Yu, H. A., & Pao, W. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.154 · Cited by 105
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
O’Leary, C. G., Gasper, H. M., Sahin, K. B., Tang, M., Kulasinghe, A., Adams, M. N., Richard, D. J., & O'Byrne, K. J. (2020) · Pharmaceuticals · doi:10.3390/ph13100273 · Cited by 114
Treatment of Non-small Cell Lung Cancer with EGFR-mutations
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2019) · Journal of UOEH · doi:10.7888/juoeh.41.153 · Cited by 111
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 111
Brameld, K. A., Owens, T. D., Verner, E. J., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00360 · Cited by 103
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09711-4 · Cited by 104
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
Singh, S. K., Sadhukhan, S., & Sonawane, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188967 · Cited by 109
Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
Yi, L., Fan, J., Qian, R., Luo, P., & Zhang, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32097 · Cited by 102
Laurie, S. A., Solomon, B., Seymour, L., Ellis, P. M., Goss, G. D., Shepherd, F. A., Boyer, M. J., Arnold, A., Clingan, P. R., Laberge, F., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.032 · Cited by 101
Self-citationEGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
Ke, E., & Wu, Y.-L. L. C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.003 · Cited by 101
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 105
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Yu, H. A., & Riely, G. J. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0024 · Cited by 99
van der Wekken, A. J., Saber, A., Hiltermann, T. J. N., Kok, K., van den -->Berg, A., & Groen, H. J. M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.024 · Cited by 99
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Santarpía, M., Liguori, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., D’Aveni, A., Marabello, G., Altavilla, G., & Rosell, R. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s119644 · Cited by 104
Kim, S. M., Yun, M. R., Hong, Y. K., Solca, F., Kim, J.-H., Kim, H. J., & Cho, B. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1188 · Cited by 100
Self-citationCheng, H., Nair, S. K., Murray, B. W., Almaden, C., Bailey, S., Baxi, S. M., Behenna, D. C., Cho-Schultz, S., Dalvie, D., Dinh, D. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01633 · Cited by 98
Remón, J., Menis, J., Hasan, B., Peric, A., Maio, E. D., Novello, S., Reck, M., Berghmans, T., Wasąg, B., Besse, B., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.02.005 · Cited by 95
Suh, C. H., Park, H. S., Kim, K. W., Pyo, J., Hatabu, H., & Nishino, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.032 · Cited by 97
Wind, S., Schmid, M., Erhardt, J., Goeldner, R.-G., & Stopfer, P. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0091-4 · Cited by 94
Wang, W., Song, Z., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.978 · Cited by 94
β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations
Nakayama, S., Sng, N., Carretero, J., Welner, R. S., Hayashi, Y., Yamamoto, M., Tan, A. J., Yamaguchi, N., Yasuda, H., Li, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0184 · Cited by 91
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Lacouture, M. E., Schadendorf, D., Chu, C., Uttenreuther‐Fischer, M., Stammberger, U. M., O’Brien, D., & Hauschild, A. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.30 · Cited by 94
Hess, L. M., Brnabic, A. J. M., Mason, O., Lee, P., & Barker, S. S. (2019) · Journal of Cancer · doi:10.7150/jca.32205 · Cited by 98
Chhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 103
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies
Campo, M. J., Gerber, D. E., Gainor, J. F., Heist, R. S., Temel, J. S., Shaw, A. T., Fidias, P., Muzikansky, A., Engelman, J. A., & Sequist, L. V. D. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.032 · Cited by 92
Profile of neratinib and its potential in the treatment of breast cancer
Kong, A. H., & Feldinger, K. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s54414 · Cited by 99
Köhler, J., & Schüler, M. (2013) · Oncology Research and Treatment · doi:10.1159/000354627 · Cited by 93
Laurie, S. A., & Goss, G. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4522 · Cited by 93
Grève, J. D., Morán, T., Graas, M.-P., Galdermans, D., Vuylsteke, P., Canon, J.-L. R., Schallier, D. C. C., Decoster, L., Teugels, E., Massey, D., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.013 · Cited by 91
Drug Resistance to EGFR Inhibitors in Lung Cancer
Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2016) · Chemotherapy · doi:10.1159/000443368 · Cited by 88
Engel, J., Lategahn, J., & Rauh, D. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00475 · Cited by 90
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
Herter-Sprie, G. S., Greulich, H. E., & Wong, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00086 · Cited by 88
Evolution of anti-HER2 therapies for cancer treatment
Parakh, S., Gan, H. K., Parslow, A. C., Burvenich, I. J. G., Burgess, A. W., & Scott, A. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.005 · Cited by 89
Direct inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith, R., & O’Bryan, J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.005 · Cited by 90
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88
Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations
Gerber, D. E., Gandhi, L., & Costa, D. B. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e353 · Cited by 89
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 88
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
Rybarczyk-Kasiuchnicz, A., Ramlau, R., & Stencel, K. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020593 · Cited by 94
Xu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Arrieta, O. G., la Torre-Vallejo, M. D., López-Macías, D., Orta, D., Turcott, J. G., Macedo-Pérez, E. O., Sánchez-Lara, K., Ramírez-Tirado, L.-A., & Baracos, V. E. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0058 · Cited by 88
Zhou, C., & Yao, L. D. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.002 · Cited by 87
Self-citationLara, P. N., Longmate, J., Mack, P. C., Kelly, K. L., Socinski, M. A., Salgia, R., Gitlitz, B. J., Li, T., Koczywas, M., Reckamp, K. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3281 · Cited by 86
Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors
Huhn, A. J., Guerra, R. M., Harvey, E. P., Bird, G. H., & Walensky, L. D. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.07.022 · Cited by 85
Tang, H., Zhu, J., Du, W., Liu, S., Zeng, Y., Ding, Z., Zhang, Y., Wang, X., Liu, Z., & Huang, J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0811-6 · Cited by 83
Paller, C. J., Bradbury, P. A., Ivy, S. P., Seymour, L., LoRusso, P. M., Baker, L. H., Rubinstein, L., Huang, E., Collyar, D. E., Groshen, S. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0521 · Cited by 85
Peters, S., Fontecedro, A. C., Nechushtan, H., Shih, J., Liao, W., Gautschi, O. P., Spataro, V. J., Unk, M., Yang, J. C., Lorence, R. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.093 · Cited by 85
Self-citationTherapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 83
Self-citationMolecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Domvri, K., Zarogoulidis, P., Darwiche, K., Browning, R. F., Jr., Li, Q., Turner, J. F., Kioumis, I. P., Spyratos, D., Porpodis, Κ., Papaiwannou, A., et al. (2013) · Journal of Cancer · doi:10.7150/jca.7734 · Cited by 82
Targeted therapies in development for non-small cell lung cancer
Dy, G. K., & Reungwetwattana, T. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.123972 · Cited by 80
Privileged Electrophile Sensors: A Resource for Covalent Drug Development
Long, M. J. C., & Aye, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.023 · Cited by 81
Aggarwal, C., Davis, C. W., Mick, R., Thompson, J. C., Ahmed, S., Jeffries, S., Bagley, S. J., Gabriel, P. E., Evans, T. L., Bauml, J. M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00107 · Cited by 79
Lin, L., & Bivona, T. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817297 · Cited by 85
Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy
Deng, X., & Nakamura, Y. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.013 · Cited by 82
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
Fu, H., Gao, H., Qi, X., Zhao, L., Wu, D., Bai, Y., Li, H., Liu, X., Hu, J. X., & Shao, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0290-3 · Cited by 80
Hirsh, V., Cadranel, J. L., Cong, X. J., Fairclough, D. L., Finnern, H. W., Lorence, R. M., Miller, V. A., Palmer, M. K., & Yang, J. C. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182773fce · Cited by 79
Self-citationLanger, C. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8782 · Cited by 79
Heigener, D. F., Schumann, C., Sebastian, M., Sadjadian, P., Stehle, I., Märten, A., Lüers, A., Griesinger, F., Scheffler, M., & for the Afatinib Compassionate Use Consortium (ACUC) (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0073 · Cited by 78
Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 81
Management of egfr tki—Induced Dermatologic Adverse Events
Melosky, B. L., Leighl, N. B., Rothenstein, J. M., Sangha, R. S., Stewart, D. J., & Papp, K. A. (2015) · Current Oncology · doi:10.3747/co.22.2430 · Cited by 78
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Burtness, B. A., Bauman, J. E., & Galloway, T. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70085-8 · Cited by 78
Hashida, S., Yamamoto, H., Shien, K., Miyoshi, Y., Ohtsuka, T., Suzawa, K., Watanabe, M., Maki, Y., Soh, J., Asano, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12749 · Cited by 79
Yu, H. A., Riely, G. J., & Lovly, C. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2437 · Cited by 80
Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
Carmi, C., Mor, M., Petronini, P. G., & Alfieri, R. R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.031 · Cited by 76
Meng, Y., Yu, B., Huang, H., Peng, Y., Li, E., Yao, Y., Song, C., Yu, W., Zhu, K., Wang, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02005 · Cited by 76
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000189 · Cited by 76
Self-citationBerger, L. A., Riesenberg, H., Bokemeyer, C., & Atanackovic, D. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.004 · Cited by 73
Huang, M.-H., Lee, J., Chang, Y., Tsai, H.-H., Lin, Y., Lin, A. M.-Y., & Yang, J. C. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.002 · Cited by 74
Self-citationRexer, B. N., Ghosh, R., Narasanna, A., Estrada, M. V., Chakrabarty, A., Song, Y., Engelman, J. A., & Arteaga, C. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1038 · Cited by 73
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Le, T., & Gerber, D. E. (2019) · Cancers · doi:10.3390/cancers11030366 · Cited by 75
Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma
Wangari‐Talbot, J., & Hopper-Borge, E. A. (2013) · Journal of cancer research updates · doi:10.6000/1929-2279.2013.02.04.5 · Cited by 80
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
In situ identification of cellular drug targets in mammalian tissue
Pang, Z., Schafroth, M. A., Ogasawara, D., Wang, Y., Nudell, V., Lal, N. K., Yang, D. U., Wang, K., Herbst, D. M., Ha, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.040 · Cited by 70
Kharbanda, A., Rajabi, H. N., Jin, C., Tchaicha, J. H., Kikuchi, E., Wong, K., & Kufe, D. W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3168 · Cited by 70
Landi, L. M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.846830 · Cited by 73
Gao, X. Y., Le, X., & Costa, D. B. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162103 · Cited by 72
Bollinger, M. K., Agnew, A. S., & Mascara, G. P. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217712401 · Cited by 69
Ellis, P. M., Coakley, N., Feld, R. D., Kuruvilla, S., & Ung, Y. (2015) · Current Oncology · doi:10.3747/co.22.2566 · Cited by 71
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh, V. (2015) · BioDrugs · doi:10.1007/s40259-015-0130-9 · Cited by 72
Self-citationLee, T., Jeong, E., Kim, S. Y., Kim, H.-R., & Kim, C. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29320 · Cited by 68
Self-citation
Metadata
- Authors
- Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., Heo, D. S., Crino, L., Tan, E.-H., Chao, T.-Y., Shahidi, M., Cong, X. J., Lorence, R. M., & Yang, J. C.-H.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- McGill University Health Centre (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- Taipei Veterans General Hospital (TW)
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Tongji University (CN)
- National Cheng Kung University Hospital (TW)
- Peking Union Medical College Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Seoul National University Hospital (KR)
- National Cancer Centre Singapore (SG)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Boehringer Ingelheim (United Kingdom) (GB)
- Boehringer Ingelheim (United States) (US)
- National Taiwan University (TW)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 13
- Issue
- 5
- Pages
- 528-538
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2152905269
- Cited by
- 961
- References
- 29
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 28 · 2023: 38 · 2022: 33 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 70 · 2017: 103 · 2016: 99 · 2015: 125 · 2014: 139 · 2013: 107 · 2012: 37
- FWCI
- 105.26
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-05-01)
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, non-small cell lung cancer, lung adenocarcinoma, EGFR tyrosine kinase inhibitors, erlotinib, gefitinib, EGFR mutation, EGFR inhibitor resistance, second-line therapy, overall survival, progression-free survival, best supportive care, targeted therapy
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Afatinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Quinazolines, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
